PTJ
AUTL

Paul Tudor Jones’s Autolus Therapeutics AUTL Stock Holding History

Paul Tudor Jones’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-46,213
Closed -$63.8K – 3539
2026
Q1 		$63.8K Sell
46,213
-235,900
-84% -$358K ﹤0.01% 3485
2025
Q4 		$561K Buy
282,113
+75,460
+37% +$116K ﹤0.01% 2663
2025
Q3 		$337K Buy
206,653
+100,000
+94% +$195K ﹤0.01% 2909
2025
Q2 		$243K Buy
+106,653
New +$176K ﹤0.01% 2999
2021
Q3 		– Sell
-13,991
Closed -$93K – 2438
2021
Q2 		$93K Buy
+13,991
New +$86.8K ﹤0.01% 1535
2020
Q3 		– Sell
-26,513
Closed -$425K – 1281
2020
Q2 		$425K Sell
26,513
-18,046
-40% -$200K 0.02% 775
2020
Q1 		$267K Buy
+44,559
New +$412K 0.02% 719

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Paul Tudor Jones's AUTL Position: Q2 2026 in Review

Paul Tudor Jones sold out of Autolus Therapeutics (AUTL) in Q2 2026, closing a stake of 46,213 shares — an estimated $63.8K sold.

Paul Tudor Jones first reported a position in AUTL in Q1 2020 and held it in 7 quarters. The position peaked at $561K in Q4 2025. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

  • Paul Tudor Jones reported no remaining Autolus Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Paul Tudor Jones sold 46,213 Autolus Therapeutics shares in Q2 2026, an estimated $63.8K.
  • Paul Tudor Jones first reported a position in Autolus Therapeutics in Q1 2020 and held it in 7 quarters.
  • Paul Tudor Jones's Autolus Therapeutics position peaked at $561K in Q4 2025.
  • 84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.